Glyburide and glipizide are approved by the FDA for treatment of symptomatic and asymp tomatic NIDDM patients in whom hyperglycemia cannot be satisfactorily controlled by diet and exercise. Pharmacology studies suggest that glyburide and glipizide sensitize the beta cells of the pancreas to release insulin only in the presence of elevated serum glucose levels. Long-term efficacy appears to depend on extrapancreatic effects, suppressing hepatic glucose production, and improved postreceptor insulin activity.
Get full access to this article
View all access options for this article.
References
1.
Griffiths MC (ed): USAN and the USP Dictionary of Drug Names , 1985. Rockville, Md, United States Pharmacopeial Convention, Inc, 235, 237, 1984.
2.
Reynolds JEF (ed): Martindale: The Extra Pharmacopoeia, ed 28. London, The Pharmaceutical Press, 1982, pp 854-855.
3.
Kolterman OG , Gray RS, Shapiro G., et al: The acute and chronic effects of sulfonylurea therapy in type II diabetic subjectsDiabetes33:346-354, 1984.
4.
DeFronzo RA, Ferrannini E:The pathogenesis of non-insulin-dependent diabetes: An updateMedicine61:125-140, 1982.
5.
Kolterman OG , Insel J., Saekow M., et al: Mechanisms of insulin resistance in human obesity: Evidence for receptor and postreceptor defectsJ Clin Invest65:1272-1284, 1980 .
6.
Bowen HF, Moorhouse JA: Glucose turnover and disposal in maturity-onset diabetesJ Clin Invest52:3033-3045, 1973 .
7.
Best JD, Judzeitsch RG, Pfeifer MA, et al: The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetesDiabetes31:333-338, 1982.
8.
Skillman TG, Feldman JM: The pharmacology of sulfonylureasAM J Med70:361-372, 1981.
9.
Pfeifer MA, Halter JB, Judzewitsch RG, et al : Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in manDiabetes Care7(suppl 1):25-34, 1984.
10.
McCaleb ML, Maloff BL, Nowak SM, et al: Sulfonylurea effects on target tissues for insulinDiabetes Care7(suppl 1):42-46, 1984.
11.
Amatruda JM , Salhanick AI, Chang CL: Hepatic insulin resistance in non-insulin-dependent diabetes mellitus and the effects of a sulfonylurea in potentiating insulin actionDiabetes Care7(suppl 1):47-53, 1984.
12.
Lebovitz HE : Cellular loci of sulfonylurea actionsDiabetes Care7(suppl 1):67-71, 1984.
13.
Olefsky JM: Current concepts regarding the pathogenesis and treatment of type II diabetes mellitus. 32nd Postgraduate Course: Current Perspectives Causes(s), Prevention and Management of Diabetes MellitusPresented at meeting of the American Diabetes Association, New Orleans , January 1985.
Porte D.: Pathophysiology of islet dysfunction in NIDDM. 32nd Postgraduate Course: Current Perspectives Causes(s), Prevention and Management of Diabetes MellitusAmerican Diabetes Association, New Orleans, January 1985.
16.
Sharpe Gwg: The adenylate cyclase-cyclic AMP system in islets of Langerhans and its role in the control of insulin releaseDiabetologia16:287-296, 1979.
17.
Goldfine ID , Perlman R., Roth J.: Inhibition of cycle 3'5'-AMP phosphodiesterase in islet cells and other tissues by tolbutamideNature234:295-297, 1971.
18.
Brooker G., Fichman M.: Chlorpropamide and tolbutamide inhibition of adenosine 31",5' cyclic monophosphate phosphodiesteraseBiochem Biophys Res Commun42:824-828, 1971.
19.
Henquin JC: Tolbutamide stimulation and inhibition of insulin release: Studies of the underlying ionic mechanisms in isolated rat isletsDiabetologia18:151-160, 1980.
20.
Asmal AC, Marble A.: Oral hypoglycaemic agents: An updateDrugs28:62-78, 1984.
21.
Kolterman OG , Olefsky JM: The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetesDiabetes Care7(suppl 1):81-88, 1984.
22.
Perley M., Kipnis DM: Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjectsDiabetes15:867-874, 1966.
23.
Chu P., Conway MJ, Krouse HA, et al: The pattern of response of plasma insulin and glucose to meals and fasting during chlorpropamide therapyAnn Intern Med68:757-769, 1968.
24.
Feldman JM, Lebovitz HE: Endocrine and metabolic effects of glybenclamide: Evidence for an extrapancreatic mechanism of actionDiabetes20:745-756, 1971.
25.
Duckworth WC , Solomon SS, Kitabchi AE: Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levelsJ Clin Endocrinol Metab35:585-591, 1972.
26.
Blumenthal SA: Potentiation of the hepatic action of insulin by chlorpropamideDiabetes26:485-489, 1977.
27.
Brogden RN, Heel RC, Pakes GE, et al: Glipizide: A review of its pharmacological properties and therapeutic useDrugs18:329-353, 1979.
28.
Raptis S., Rau RM, Schroder KE, et al: Comparative study of insulin secretion following repeated administration of glucose, tolbutamide, and glibenclamide (HB 419) in diabetic and non-diabetic human subjectsHorm Metab Res1(suppl):65-72, 1969.
29.
Sartor G., Melander A., Schersten B., et al : Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamideDiabetologia18:17-22, 1980.
30.
Lawrence JR , Gray CE, Dunnigan MG: The glucose dependence of glipizide-induced insulin secretion, in Glipizide: A Worldwide Review. Excerpta Med1984.
31.
DeFronzo FA , Simonson DC: Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individualsDiabetes Care7(Suppl 1):72-80, 1984.
32.
Beck-Nielsen H., Hjollund E., Pedersen O., et al: Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitusDiabetes Care7(suppl 1):100-105, 1984.
33.
Chandalia HB , Hollobaugh SL, Pennington LF, et al: Use of glibenclamide in maturity-onset diabetes: Effects of the drug on serum insulin levelsHorm Metab Res1(suppl):73-76, 1969.
34.
Beck-Nielsen H., Pedersen O., Lindskov HO: Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamideActa Endocrinol90:451-462, 1979.
35.
Lebovitz HE, Feinglos MN, Bucholtz HK, et al: Increased insulin effectiveness : An extrapancreatic action of glipizide in man, in Glipizide: A Worldwide ReviewPrinceton, N.J. : Excerpta Med1984.
36.
Lebovitz HE, Feinglos MN: Extrapancreatic effects of sulfonylureas: Evidence for potentiation of insulin action and increase in plasma membrane insulin receptors as a mechanism for antidiabetic action, in Glipizide: A Worldwide ReviewPrinceton, N.J.: Excerpta Med1984.
37.
Klaff LJ, Kernoff L., Vink AJ, et al: Sulfonylureas and platelet functionAm J Med70:627-630, 1981.
38.
Dobbie JG, Kwann HC, Colwell J., et al: The role of platelets in pathogenesis of diabetic retinopathyTrans Am Acad Ophthalmol Otorlaryngol77:43-52, 1973.
39.
O'Malley BC , Ward JD, Timperly WR, et al: Platelet abnormalities in diabetic peripheral neuropathyLancet2:1274-1275, 1975.
40.
Ylikorkala O., Kaila J., Viinikka L.: Prostacyclin and thromboxane in diabetesBr Med J281:1148-1150, 1981 .
41.
Colwell JA, Halushka PV, Sarji KE, et al: Platelet function and diabetes mellitusMed Clin North Am62:753-766, 1978.
42.
Balant L., Zahnd G., Gorgia A., et al: Pharmacokinetics of glipizide in man: Influence of renal insufficiencyDiabetologia9(suppl):331-338, 1973.
43.
Wahlin-Boll E. , Almer LO, Melander A.: Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabeticsClin Pharmacokinet7:363-372, 1982.
44.
Schmidt Hae, Schoog M., Schweer KH, et al: Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabeticDiabetologia9(suppl):320-330, 1973.
45.
Ostman J., Christenson I., Jansson B., et al: The antidiabetic effect and pharmacokinetic properties of glipizideActa Med Scand210:173-180, 1981.
46.
Peterson CM, Sims RV, Jones RL, et al: Bioavailability of glipizide and its effect on blood glucose and insulin levels in patients with non-insulin-dependent diabetesDiabetes Care5:497-500, 1982.
47.
Wahlin-Boll E., Melander A., Sartor G., et al: Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjectsEur J Clin Pharmacol18:279-283, 1980.
48.
Sartor G., Sehersten B., Melander A.: Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patientsActa Med Scand203:211-214, 1978.
49.
Pentikainen FJ, Neuvonen PJ, Penttila A.: Pharmacokinetics and pharmacodynamics of glipizide in man, abstractedClin Pharmacol Ther29:272, 1981.
50.
MacWalter RS , El Debani AH, Feely J., et al: Studies on glipizide pharmacokinetics and effect in diabetic patientsBr J Clin Pharmacol17:622, 1984.
51.
Balant L., Fabre J.: Pharmacokinetics of glipizide in man, in Glipizide: A Worldwide ReviewPrinceton, N.J.: Excerpta Med1984.
52.
Balant L., Fabre J., Zahnd G.: Comparison of the pharmacokinetics of glipizide and glibenclamide in manEur J Clin Pharmacol8:63-69, 1975.
53.
Fuccella LM, Tamassia V, Valzelli G.: Metabolism and kinetics of the hypoglycemia agent glipizide in man—comparison with glibenclamideJ Clin Pharmacol13:68-75, 1973.
54.
Balant L.: Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugsClin Pharmacokinet6:215-241, 1981.
55.
Product Information: GlucotrolRoerig, New York, 1984.
56.
Shuman CR: Glipizide: An overviewAm J Med74:55-59, 1983.
57.
Sachs R., Frank M., Fishman SK: Overview of clinical experience with glipizide, in Glipizide: A Worldwide ReviewExcerpta Med163-172, 1984.
58.
Benfield Gfa , Pettengell KE, Hunter KR: Once-daily vs twice daily glipizide in diabetes mellitusBr J Clin Pharmacol14:614, 1982.
59.
Duncan Ljp, Clarke BF, Corrall Rjm, et al: Clinical observations on dose-range experience, in Glipizide: A Worldwide ReviewPrinceton, N.J.: Excerpta Med95-102, 1984.
60.
Rupp W., Christ O., Heptner W.: Resorption, Ausscheidung und Metabolismus nach intravenoser und oraler Gabe von HB 419 14-C an MenschenArzneimittelforsch19:1428-1434, 1969.
61.
Schmidt Hae , Petrides P.: Glukose- und HB 419-Konzentration im Blut sowie HB 419-Ausscheidung im Urin nach einmaliger oraler Applikation von GlibenclamidArzneimittelforsch19:1422-1428, 1969.
62.
Balant L., Zahnd GR, Weber F., et al: Behaviour of glibenclamide on repeated administration to diabetic patientsEur J Clin Pharmacol11:19-25, 1977.
63.
Rupp W., Christ O., Fullberth W.: Untersuchungen zur Bioavailability von GlibenclamidArzneimittel-Forschung22:471-473, 1972.
64.
Ko H., Royer ME, Molony BA: Relationship between circulating glyburide/metabolite concentrations, serum glucose lowering, and dose of glyburide in manExcerpta Med382:20-30, 1975.
Pearson JG, Antal EJ, Alber KS, et al: Pharmacokinetic disposition of 14-C-glyburide in patients with varying renal function, abstractedDiabetes33(suppl):104a, 1984.
68.
National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose toleranceDiabetes28:1309-1357, 1979.
69.
Lebovitz HE : Clinical utility of oral hypoglycemic agents in the management of patients with non-insulin-dependent diabetes mellitusAm J Med74:94-99, 1983.
70.
Seltzer HSObjectives of treatment and modes of hypoglycemic therapy, in Glipizide: A Worldwide ReviewExcerpta Med222-233, 1984.
71.
Beyer J., Schoffling K.: Clinical experience with glybenclamide in 300 diabeticsPostgrad Med J46(suppl):78-83, 1970.
72.
Stravinski S., Loave SJ: Long-term experience with glipizide, in Glipizide: A Worldwide ReviewExcerpta Med291-295, 1984.
73.
Labeling for oral hypoglycemic drugs of the sulfonylurea classFederal Register49:14331 (April 11) 1984.
74.
Briggs GG, Bodendorfer TW, Freeman RK, et al: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal RiskBaltimore, Williams & Wilkins Co, 1983.
75.
Crim JA, Molongy BA, Gundersen K., et al : The effects of Micronase (glyburide) on thyroid function and platelet count in maturity-onset diabeticsExcerpta Med382:241-247, 1975.
76.
Stotter G., Szabo J., Kohler W.: Thyroid functions during long-term therapy with HB 419Arzneimittelforsch19:1436-1439, 1969 .
77.
Moses AM: Effects of sulfonylurea drugs on water metabolismExcerpta Med382:105-119, 1975.
78.
Ravina A.: Antidiuretic action of chlorpropamide, letterLancet2:203, 1973.
79.
Garcia M., Miller M., Moses AM: Chlorpropamide-induced water retention in patients with diabetes mellitusAnn Intern Med75:549-554, 1971.
80.
Rado JP, Borbely L., Szende L., et al: Investigation of the diuretic effect of glibenclamide in healthy subjects and in patients with pituitary and nephrogenic diabetes insipidusHorm Metab Resb289-292, 1974.
81.
Preuss HG, et al: Effects of glipizide on water and electrolyte handling in water-loaded humansRenal Physiol4:173-179, 1981.
82.
Hansten PD: Drug Interactions, ed 5. Philadelphia , Lea & Febiger, 1985, pp 150-169.
83.
Crooks MJ, Brown KF: Binding of sulfonylureas to serum albuminJ Pharm Sci62:1904-1906, 1973.
84.
Hobbs DC, Taylor JA: Glipizide: Pharmacokinetics and biotransformation, in Glipizide: A Worldwide Review. Excerpta Med83-94, 1984.
85.
Crooks MJ, Brown KF: The binding of sulfphonylureas to serum albuminJ Pharm Pharmacol26:304-311, 1974.
86.
Hsu P., Ma Jkh, Luzzi LA: Interactions of sulfonylureas with plasma proteinsJ Pharm Sci63:570-573, 1974.
87.
Brown KF, Crooks MJ: Displacement of tolbutamide, glibenclamide and chlorpropamide from serum albumin by anionic drugsBiochem Pharmacol25:1175-1178, 1976.
88.
Nilsson B., Agren A.: Complex formation between macromolecules and drugsActa Pharm Suec11:391-400, 1974.
89.
Podgainy H. , Bressler R.: Biochemical basis of sulfonylurea-induced Antabuse syndromeDiabetes71:679-683, 1968.
90.
Wiseman EH: Pharmacological studies of glipizide, in Glipizide: A Worldwise ReviewPrinceton, N.J.: Excerpta Med1984.
91.
Clyne JR, Cohen H.: Alcohol and glibenclamideBr Med J3:533-1971.
92.
O'Sullivan DJ, Cashman WF: Blood glucose variations and clinical experience with glibenclamide in diabetes mellitusBr Med J1:572-574, 1970.
93.
Luyckx A., Lefebvre P.: Clinical study of a new oral antidiabetic drug: Glibenclamide (HB 419)Rev Med Liege25:111-116, 1970.
94.
Clarke BF, Corrall Rjm, Azzopardi J., et al : Clinical observations in glipizide: Efficacy, duration of activity, and safety, in Glipizide: A Worldwide ReviewPrinceton, N.J.: Excerpta Med1984.
95.
Wardle EN, Richardson GO: Alcohol and glibenclamideBr Med J2:309, 1971.
